Propranolol for the treatment of vascular sarcomas

Michael J. Wagner, Lee D Cranmer, Elizabeth T. Loggers, Seth M. Pollack

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalJournal of Experimental Pharmacology
Volume10
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Propranolol
Sarcoma
Blood Vessels
Hemangioma
Neoplasms
Hemangiosarcoma
Adrenergic Receptors
Endothelial Cells

Keywords

  • Angiosarcoma
  • Cancer
  • Propranolol
  • Vascular sarcoma
  • β-blocker

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmacology (medical)

Cite this

Propranolol for the treatment of vascular sarcomas. / Wagner, Michael J.; Cranmer, Lee D; Loggers, Elizabeth T.; Pollack, Seth M.

In: Journal of Experimental Pharmacology, Vol. 10, 01.01.2018, p. 51-58.

Research output: Contribution to journalReview article

Wagner, Michael J. ; Cranmer, Lee D ; Loggers, Elizabeth T. ; Pollack, Seth M. / Propranolol for the treatment of vascular sarcomas. In: Journal of Experimental Pharmacology. 2018 ; Vol. 10. pp. 51-58.
@article{24d5f54579fd49c4981824867ad7d70a,
title = "Propranolol for the treatment of vascular sarcomas",
abstract = "Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.",
keywords = "Angiosarcoma, Cancer, Propranolol, Vascular sarcoma, β-blocker",
author = "Wagner, {Michael J.} and Cranmer, {Lee D} and Loggers, {Elizabeth T.} and Pollack, {Seth M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/JEP.S146211",
language = "English (US)",
volume = "10",
pages = "51--58",
journal = "Journal of Experimental Pharmacology",
issn = "1179-1454",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Propranolol for the treatment of vascular sarcomas

AU - Wagner, Michael J.

AU - Cranmer, Lee D

AU - Loggers, Elizabeth T.

AU - Pollack, Seth M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.

AB - Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.

KW - Angiosarcoma

KW - Cancer

KW - Propranolol

KW - Vascular sarcoma

KW - β-blocker

UR - http://www.scopus.com/inward/record.url?scp=85059036661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059036661&partnerID=8YFLogxK

U2 - 10.2147/JEP.S146211

DO - 10.2147/JEP.S146211

M3 - Review article

AN - SCOPUS:85059036661

VL - 10

SP - 51

EP - 58

JO - Journal of Experimental Pharmacology

JF - Journal of Experimental Pharmacology

SN - 1179-1454

ER -